Metoject solution 7.5 mg 0.15 ml 50 mg/ml methotrexate Cancer Методжект

Metoject Indications

- Active form of rheumatoid arthritis of adults
- Polyarthritis hard form of juvenile (idiopathic) arthritis, in case of inadequate response to non-steroidal anti-inflammatory drugs;
severe form of psoriasis, especially in the form of plaques, in the event of ineffectiveness of appropriate therapy, such as phototherapy, PUVA therapy and the use of retinoids, as well as in severe psoriasis arthritis in adults
- Lung and moderate Crohn's disease (as monotherapy or in combination with corticosteroids) in adults, in the case of resistance or intolerance to thiopurines

Contradictions

- hypersensitivity to methotrexate or to any of the components;
- liver dysfunction (liver disease caused by alcohol, or other chronic liver disease);
- alcohol abuse;
- blood diseases in history, such as bone marrow hypoplasia, leukocytopenia, thrombocytopenia or severe anemia;
- severe acute or chronic infections such as tuberculosis and HIV, or other immunodeficiency syndromes;
- ulcers in the oral cavity and ulcers in the stomach or intestine in active form;
- renal impairment (creatinine clearance less than 60 ml / min);
- concomitant vaccination with live vaccines;
- pregnancy and breastfeeding.

Dosage & Administration

The appointment of Metoject should be by doctors who have experience and know all the features of this drug and its mechanism of action.

Metoject should be administered once a week.

The patient should be clearly informed that the drug should be administered once a week. It is advisable to set a fixed day of the week as an injection day.